Bimiralisib,
PQR309,
1225037-39-7,
PI3K-IN-2,
PQR-309,
UNII-6Z3QHB00LB,
6Z3QHB00LB,
5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine,
5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine,
5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine,
Bimiralisib [INN],
pqr309-bimiralisib,
Bimiralisib [USAN],
PQR309; Bimiralisib,
Bimiralisib [WHO-DD],
NCB5,
Bimiralisib (PQR309),
GTPL8383,
SCHEMBL1309049,
CHEMBL4084907,
PQR309; Bimiralisib free base,
ADGGYDAFIHSYFI-UHFFFAOYSA-N,
BCP15887,
EX-A2018,
PQR-309(PI3K-IN-2),
MFCD28902193,
ZINC68203488,
AKOS027439949,
CS-4672,
AK499419,
AS-49856,
HY-12868,
2-Pyridinamine, 5-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-,
5-(4,6-Di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-2-pyridinamine,
A3W,
D0TU7B,
A15992,